A small team of materials scientists and chemical engineers at Qingdao University, in China, has developed a self-powered, ...

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins ...

Immunotherapies use antibodies—proteins that bind to cell ... complex proteins like E. coli. Applying it to human proteins ...

The device consists of glass capillary tubes with light emitting diode (LED) lights on either end. E. coli antibodies are fixed to the sides of the capillaries and trap any E. coli present in a liquid ...

“I used to work with E. coli for protein expression ... Cell lines commonly used for monoclonal antibody expression include Chinese hamster ovary (CHO) and human embryonic kidney 293 (HEK293 ...

Because we produce recombinantly large amounts of different vascular-related proteins (such as VEGFs, their receptors, antibodies) using E. coli, yeast, insect cells, and mammalian cells, we started ...

The predominant pathotype was Enteroaggregative E. coli (EAEC), accounting for 47.3% of the isolates, with notable variations in resistance across different age groups—especially infants under ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli. Sanofi recorded a $250 ...

EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced it will award US$2 million to Immunethep SA to develop a conjugated peptide-based vaccine to prevent ...

EffiXTM is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a ...